Related Experiment Videos
High-versus low-dose erythropoietin in extremely low birth weight infants. The European Multicenter rhEPO Study Group
R F Maier1, M Obladen, E Kattner
1Department of Neonatology, Charité-Virchow-Klinikum, Humboldt-Universität Berlin, Germany.
Insights
Doubling recombinant human erythropoietin (rhEPO) dosage to 1500 IU/kg/week did not improve anemia prevention or reduce transfusion needs in premature infants. The higher rhEPO dose offered no significant benefit over 750 IU/kg/week.
Area of Science:
- Neonatal Medicine
- Pediatric Hematology
- Pharmacology
Background:
- Premature infants, particularly those with very low birth weights (<1000 gm), are at high risk for anemia of prematurity.
- Erythropoiesis-stimulating agents like recombinant human erythropoietin (rhEPO) are used to manage anemia in this population.
- Optimal dosing strategies for rhEPO in extremely low birth weight infants remain an area of investigation.
Purpose of the Study:
- To compare the efficacy of a high dose (1500 IU/kg/week) versus a standard dose (750 IU/kg/week) of rhEPO in preventing anemia.
- To assess the impact of different rhEPO doses on the need for blood transfusions in infants weighing less than 1000 gm at birth.
- To determine if a higher rhEPO dose leads to a better clinical outcome defined by transfusion avoidance and adequate hematocrit levels.
Main Methods:
- A randomized, double-blind, multicenter clinical trial was conducted.
- 184 infants with birth weights ranging from 500 to 999 gm were enrolled.
- Participants received either 750 IU/kg/week (low-dose) or 1500 IU/kg/week (high-dose) of rhEPO from day 3 of life until 37 weeks' corrected age.
Main Results:
- No significant difference in the rate of transfusion avoidance was observed between the low-dose and high-dose rhEPO groups (32% in each group).
- The total volume of erythrocyte transfusions administered was comparable across both treatment arms.
- The success rate, defined as no transfusion requirement and a hematocrit ≥0.30 L/L, was similar: 27.6% for the low-dose group and 29.5% for the high-dose group (p=0.96).
Conclusions:
- Increasing the weekly dose of rhEPO from 750 IU/kg to 1500 IU/kg does not provide additional benefits in preventing anemia or reducing transfusion requirements in infants with birth weights under 1000 gm.
- The standard dose of 750 IU/kg/week appears to be sufficient for managing anemia in this vulnerable infant population.
- Further research may explore other factors influencing transfusion needs in extremely low birth weight infants.
Objective:
To investigate whether a weekly 1500 IU/kg dose of recombinant human erythropoietin (rhEPO) is more effective than a dose of 750 IU/kg/week in preventing anemia and reducing the transfusion need in infants with birth weights less than 1000 gm.
Study Design:
In a randomized, double-blind, multicenter trial, 184 infants with birth weights between 500 and 999 gm were treated with either rhEPO 750 (low-dose group) or 1500 IU/kg/week (high-dose group) from day 3 of life until 37 weeks' corrected age.
Results:
Thirty-two percent of the infants in each group did not receive any transfusion during the treatment period. The total volume of erythrocytes received was similar in each group. The success rate, defined as no transfusion needed and hematocrit value 0.30 L/L or greater, was 27.6% in the low-dose and 29.5% in the high-dose group (p = 0.96).
Conclusion:
Doubling the rhEPO dose of 750 IU/kg/week is not indicated in infants with birth weights less than 1000 gm.